A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

Inclusion Criteria: * Ability to read, understand and provide written consent to participate in the study * Age ≥ 18 years * Biopsy-proven well-differentiated, low-to-intermediate-grade PNET or GI-NET with elevated (\> ULN) biomarkers (serotonin, 5-hydroxyindoleacetic acid (5-HIAA), chromogranin A (CgA), neurokinin A, and neuron-specific enolase (NSE)) * Life expectancy \> 12 weeks * Must have received or may still be receiving one or more therapies including octreotide or serotonin synthesis inhibitor (SSI) or other somatostatin analogues * Confirmed progressive disease within 18 months of enrollment on study * Recovered from prior radiation therapy or surgery * Eastern Cooperative Oncology Group (ECOG) performance score 0-2 * Absolute neutrophil count (ANC) ≥ 1,500/µL (without growth factors) * Platelet count ≥ 100,000/µL * Adequate renal function as evidenced by serum creatinine ≤ 2.0 mg/dL (177 µmol/L) * Adequate hepatic function: serum total bilirubin ≤ 2X greater than the upper limit of normal (ULN) (≤ 3X ULN in subjects with liver metastases), aspartate aminotransferase) AST) / alanine aminotransferase (AST) ≤ 2X the ULN for the local reference lab (≤ 5X the ULN for subjects with liver metastases) * Disease that can be assessed (evaluable) with imaging (CT, MRI, PET, radionuclide imaging or other imaging modality) * Women of childbearing potential as well as fertile men and their partners must use an effective method of birth control Exclusion Criteria: * Inadequ…